The associations between plasma soluble Trem1 and neurological diseases: a Mendelian randomization study

Table 4 Heterogeneity and pleiotropy tests for the associations of plasma Trem1 levels with neurological diseases

Outcome	Cochrane’s Q test		MR-Egger intercept test		MRPRESSO global test
Outcome	Q-value	P_Q	Intercept	P_intercept	P value
Neurodegenerative disease
Alzheimer’s disease	16.596	0.278	− 0.006	0.653	0.155
Parkinson’s disease	19.716	0.233	− 0.034	0.014	0.265
Amyotrophic lateral sclerosis	8.030	0.986	− 0.005	0.624	0.986
Multiple sclerosis	15.002	0.132	− 0.006	0.720	0.292
Epilepsy
epilepsy	4.352	0.629	0.007	0.399	0.758
Generalized epilepsy	1.460	0.918	− 0.004	0.764	0.973
Focal epilepsy	7.540	0.183	0.018	0.113	0.352
Cerebrovascular diseases
Ischemic stroke	14.960	0.528	− 0.001	0.869	0.632
Large-artery atherosclerosis	11.741	0.762	0.006	0.753	0.777
Small-vessel	27.771	0.023	0.006	0.807	0.068
Cardioembolic	20.504	0.198	− 0.007	0.682	0.245
Nontraumatic intracranial hemorrhage	11.070	0.523	− 0.011	0.638	0.654
Subarachnoid hemorrhage	7.993	0.786	0.005	0.882	0.657
Migraine
Migraine with aura	13.523	0.634	0.027	0.127	0.229
Migraine without aura, drug-induced	8.291	0.940	0.048	0.508	0.932
Migraine without aura and triptan purchases	9.061	0.911	− 0.005	0.780	0.921

Bold symbol indicated statistically significances (P < 0.05)
MR-PRESSO: Pleiotropy Residual Sum and Outlier; sTrem1: soluble triggering receptor expressed on myeloid cell 1

ISSN: 1742-2094